ArticleNeuromolecular medicine2025
When Heroes Fall: Reduced Expression of Heat-Resistant Obscure Proteins in Ischemic Stroke.
Article in Neuromolecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic Variants in HSP70 Family and BAG Co-Chaperone Genes: Associations with Coronary Artery Disease Risk and Potential Regulatory Effects.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The recently discovered family of heat-resistant obscure (Hero) proteins represents a novel class with chaperone-like activity and unique protective properties. These proteins may contribute to cellular survival in ischemic stroke (IS) conditions. Herein, we aimed to investigate the expression dynamics of six Hero genes during the acute and subacute phases of IS. Peripheral blood samples were collected from IS patients in the acute (day 1, n = 47) and subacute (day 7, n = 41) phases, along with healthy controls (n = 42). Gene expression was assessed via quantitative PCR. Statistical analysis included group comparisons, multivariate regression modelling, and correlation analysis. In the acute phase, C9orf16 (P = 0.006), C11orf58 (P = 0.00001), and SERBP1 (P = 0.006) were significantly downregulated compared to controls. By day 7, SERBP1 expression normalized, while C9orf16 (P = 0.002) and C11orf58 (P = 0.0004) remained downregulated. Multivariate regression identified C11orf58 expression as a potential biomarker of IS. Expression levels of SERBP1 and C11orf58 negatively correlated with infarct size during both the acute (R = - 0.59, P = 0.00012; R = - 0.49, P = 0.004) and subacute phases (R = - 0.54, P = 0.0024; R = - 0.44, P = 0.032). eQTL analysis showed that SERBP1 SNPs were associated with reduced expression only in controls. Our findings underscore the potential relevance of Hero proteins as biomarkers or therapeutic targets in IS, warranting further investigation into their mechanistic involvement in neuroprotection and recovery.
Indexed as
Identifiers
40906246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.